Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'PALLIATIVE END-POINTS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 32 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Oudard, S; Caty, A; Humblet, Y; Beauduin, M; Suc, E; Piccart, M; Rolland, F; Fumoleau, P; Bugat, R; Houyau, P; Monnier, A; Sun, X; Montcuquet, P; Breza, J; Novak, J; Gil, T; Chopin, D
      Phase II study of vinorelbine in patients with androgen-independent prostate cancer

      ANNALS OF ONCOLOGY
    2. Heidenreich, A; von Knobloch, R; Hofmann, R
      Current status of cytotoxic chemotherapy in hormone refractory prostate cancer

      EUROPEAN UROLOGY
    3. Willan, AR; O'Brien, BJ; Leyva, RA
      Cost-effectiveness analysis when the WTA is greater than the WTP

      STATISTICS IN MEDICINE
    4. Willan, AR; Lin, DY
      Incremental net benefit in randomized clinical trials

      STATISTICS IN MEDICINE
    5. Willan, AR
      Analysis, sample size, and fewer for estimating incremental net health benefit from clinical trial data

      CONTROLLED CLINICAL TRIALS
    6. Kucuk, O; Fisher, E; Moinpour, CM; Coleman, D; Hussain, MHA; Sartor, AO; Chatta, GS; Lowe, BA; Eisenberger, MA; Crawford, ED
      Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235)

      UROLOGY
    7. Sherman, EJ; Pfister, DG; Ruchlin, HS; Rubin, DM; Radzyner, MH; Kelleher, GH; Slovin, SF; Kelly, WK; Scher, HI
      The collection of indirect and nonmedical direct costs (COIN) form - A newtool for collecting the invisible costs of androgen independent prostate carcinoma

      CANCER
    8. Huan, SD; Natale, RB; Stewart, DJ; Sartiano, GP; Stella, PJ; Roberts, JD; Symes, AL; Finizio, M
      A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer

      CLINICAL CANCER RESEARCH
    9. Culine, S; Droz, JP
      Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: Adecade of progress?

      ANNALS OF ONCOLOGY
    10. Bracarda, S; Tonato, M; Rosi, P; De Angelis, V; Mearini, E; Cesaroni, S; Fornetti, P; Porena, M
      Oral estramustine and cyclophosphamide in patients with metastatic hormonerefractory prostate carcinoma - A phase II study

      CANCER
    11. Culine, S
      News on the medical treatment of urological tumors

      BULLETIN DU CANCER
    12. Rosenthal, MA
      Advances in the management of prostate cancer

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    13. Auclerc, G
      Systemic therapy in metastatic prostate cancer

      ANNALES D UROLOGIE
    14. Sommers, SD; Ramsey, SD
      A review of quality-of-life evaluations in prostate cancer

      PHARMACOECONOMICS
    15. Fields-Jones, S; Koletsky, A; Wilding, G; O'Rourke, M; O'Rourke, T; Eckardt, J; Yates, B; McGuirt, C; Burris, HA
      Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial

      ANNALS OF ONCOLOGY
    16. Gleave, ME; Bruchovsky, N; Moore, MJ; Venner, P
      Prostate cancer: 9. Treatment of advanced disease

      CANADIAN MEDICAL ASSOCIATION JOURNAL
    17. Litwin, MS; Fitzpatrick, JM; Fossa, SD; Newling, DWW
      Defining an international research agenda for quality of life in men with prostate cancer

      PROSTATE
    18. Kim, J; Logothetis, CJ
      Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma

      UROLOGIC CLINICS OF NORTH AMERICA
    19. Smith, DC
      Chemotherapy for hormone refractory prostate cancer

      UROLOGIC CLINICS OF NORTH AMERICA
    20. Roth, BJ
      Androgen-independent prostate cancer: Not so chemorefractory after all

      SEMINARS IN ONCOLOGY
    21. Hussain, M; Petrylak, D; Fisher, E; Tangen, C; Crawford, D
      Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group study 9916

      SEMINARS IN ONCOLOGY
    22. Dawson, NA
      Response criteria in prostatic carcinoma

      SEMINARS IN ONCOLOGY
    23. Petrylak, DP
      Chemotherapy for advanced hormone refractory prostate cancer

      UROLOGY
    24. DAWSON N; FIGG WD; BRAWLEY OW; BERGAN R; COOPER MR; SENDEROWICZ A; HEADLEE D; STEINBERG SM; SUTHERLAND M; PATRONAS N; SAUSVILLE E; LINEHAN WM; REED E; SARTOR O
      PHASE-II STUDY OF SURAMIN PLUS AMINOGLUTETHIMIDE IN 2 COHORTS OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER - SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND PRIOR ANTIANDROGEN WITHDRAWAL

      Clinical cancer research
    25. DAWSON N; FIGG WD; BRAWLEY OW; BERGAN R; COOPER MR; SENDEROWICZ A; HEADLEE D; STEINBERG SM; SUTHERLAND M; PATRONAS N; SAUSVILLE E; LINEHAN WM; REED E; SARTOR O
      PHASE-II STUDY OF SURAMIN PLUS AMINOGLUTETHIMIDE IN 2 COHORTS OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER - SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND PRIOR ANTIANDROGEN WITHDRAWAL

      Clinical cancer research
    26. JUNGI WF; BERNHARD J; HURNY C; SCHMITZ SFH; HANSELMANN S; GUSSET H; PESTALOZZI D; GOLDHIRSCH A
      EFFECT OF CARBOPLATIN ON RESPONSE AND PALLIATION IN HORMONE-REFRACTORY PROSTATE-CANCER

      Supportive care in cancer
    27. STOCKLER MR; OSOBA D; GOODWIN P; COREY P; TANNOCK IF
      RESPONSIVENESS TO CHANGE IN HEALTH-RELATED QUALITY-OF-LIFE IN A RANDOMIZED CLINICAL-TRIAL - A COMPARISON OF THE PROSTATE-CANCER SPECIFIC QUALITY-OF-LIFE INSTRUMENT (PROSQOLI) WITH ANALOGOUS SCALES FROM THE EORTC QLQ-C30 AND A TRIAL SPECIFIC MODULE

      Journal of clinical epidemiology
    28. Pilat, MJP; Kamradt, JM; Pienta, KJ
      Hormone resistance in prostate cancer

      CANCER AND METASTASIS REVIEWS
    29. Reese, DM; Tchekmedyian, S; Chapman, Y; Prager, D; Rosen, PJ
      A phase II trial of irinotecan in hormone-refractory prostate cancer

      INVESTIGATIONAL NEW DRUGS
    30. KNIGHT SJ; CHMIEL JS; KUZEL T; SHARP L; ALBERS M; FINE R; MORAN EM; NADLER RB; SHARIFI R; BENNETT CL
      QUALITY-OF-LIFE IN METASTATIC PROSTATE-CANCER AMONG MEN OF LOWER SOCIOECONOMIC-STATUS - FEASIBILITY AND CRITERION-RELATED VALIDITY OF 3 MEASURES

      The Journal of urology
    31. VOGELZANG NJ; CRAWFORD ED; ZIETMAN A
      CURRENT CLINICAL-TRIAL DESIGN ISSUES IN HORMONE-REFRACTORY PROSTATE CARCINOMA

      Cancer
    32. ESPER P; MO F; CHODAK G; SINNER M; CELLA D; PIENTA KJ
      MEASURING QUALITY-OF-LIFE IN MEN WITH PROSTATE-CANCER USING THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY PROSTATE INSTRUMENT

      Urology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 01:04:19